Codexis (NASDAQ:CDXS) gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $11.50, but opened at $10.70. Codexis shares last traded at $10.40, with a volume of 2866513 shares.
Specifically, Director Thomas R. Baruch sold 25,000 shares of Codexis stock in a transaction on Thursday, March 29th. The stock was sold at an average price of $11.05, for a total transaction of $276,250.00. Following the completion of the transaction, the director now directly owns 184,670 shares of the company’s stock, valued at $2,040,603.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bernard J. Kelley sold 10,206 shares of Codexis stock in a transaction on Wednesday, March 21st. The shares were sold at an average price of $12.22, for a total value of $124,717.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,337 shares of company stock valued at $1,187,683. Company insiders own 9.80% of the company’s stock.
A number of research firms recently issued reports on CDXS. HC Wainwright set a $12.00 price target on Codexis and gave the company a “buy” rating in a report on Monday, March 12th. ValuEngine raised Codexis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research cut Codexis from a “hold” rating to a “sell” rating in a report on Wednesday, March 14th. Finally, BidaskClub cut Codexis from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Codexis has a consensus rating of “Buy” and a consensus price target of $9.75.
The company has a quick ratio of 1.76, a current ratio of 1.80 and a debt-to-equity ratio of 0.02. The firm has a market cap of $523.08, a PE ratio of -20.80 and a beta of -1.73.
Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.03). Codexis had a negative net margin of 45.97% and a negative return on equity of 103.42%. The business had revenue of $21.70 million during the quarter, compared to the consensus estimate of $22.97 million. During the same period in the prior year, the firm earned ($0.07) earnings per share. The business’s quarterly revenue was up 117.0% compared to the same quarter last year. equities analysts predict that Codexis will post -0.25 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in CDXS. Thompson Davis & CO. Inc. raised its holdings in Codexis by 1,753.5% during the 4th quarter. Thompson Davis & CO. Inc. now owns 18,535 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 17,535 shares during the last quarter. Burney Co. bought a new stake in Codexis during the 4th quarter worth about $167,000. MetLife Investment Advisors LLC bought a new stake in Codexis during the 4th quarter worth about $179,000. Virtu Financial LLC bought a new stake in Codexis during the 4th quarter worth about $202,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Codexis by 30.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 8,244 shares during the last quarter. 70.84% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/codexis-cdxs-shares-gap-down-after-insider-selling.html.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.